Kruti B Shah1, David A Fields2, Nathan P Pezant3, Harmeet K Kharoud4, Shelly Gulati2, Katherine Jacobs5, Cheryl A Gale6, Elyse O Kharbanda7, Emily M Nagel4, Ellen W Demerath4, Jeanie B Tryggestad2. 1. Section of Pediatric Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Electronic address: kruti-shah@ouhsc.edu. 2. Section of Pediatric Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. 3. Oklahoma Medical Research Foundation, Department of Genes and Human Disease, Oklahoma City, Oklahoma. 4. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota. 5. Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota. 6. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. 7. HealthPartners Institute, Minneapolis, Minnesota.
Abstract
PURPOSE: Human milk (HM) is a unique biological fluid that is enriched with a variety of factors, including microRNAs (miRNAs) that potentially provide both short- and long-term benefits to the infants. miRNAs are packaged within exosomes, making them bioavailable to infants. Gestational diabetes mellitus (GDM) may affect the abundance of exosomal miRNAs in HM, providing a mechanism for growth and adiposity variation in infants of mothers with GDM in early life. Therefore, the purposes of this study were to examine the impact of GDM on select miRNAs (miRNA-148a, miRNA-30b, miRNA-let-7a, and miRNA-let-7d) involved in metabolism and to examine the association of these miRNAs with measures of infant body composition in the first 6 months of life. METHODS: Milk samples were collected from a cohort of 94 mothers (62 mothers without GDM and 32 mothers with GDM) matched on body mass index strata at 1 month post partum. miRNA abundance was measured by real-time polymerase chain reaction. Linear regression models were used to examine potential differences in miRNA abundance in women with and without GDM, testing associations between miRNA abundance and infant growth and body composition measures from 1 to 6 months. FINDINGS: The abundances of miRNA-148a, miRNA-30b, miRNA-let-7a, and miRNA-let-7d were reduced in milk from mothers with GDM. Independent of GDM status, higher maternal diet quality was associated with increased abundance of each of the measured miRNAs. miRNA-148a was negatively associated with infant weight, percentage of body fat, and fat mass, whereas miRNA-30b was positively associated with infant weight and fat mass at 1 month of age. There was no association of milk miRNA-148a and miRNA-30b with infant weight at 1 month of age or with body composition measures at 3 months of age; however, miRNA-148a was negatively associated with infant weight at 6 months of age. IMPLICATIONS: If supported by randomized dietary supplementation or other intervention trials, HM miRNAs may be a therapeutic target to mitigate risk of metabolic outcomes in offspring of women with GDM.
PURPOSE: Human milk (HM) is a unique biological fluid that is enriched with a variety of factors, including microRNAs (miRNAs) that potentially provide both short- and long-term benefits to the infants. miRNAs are packaged within exosomes, making them bioavailable to infants. Gestational diabetes mellitus (GDM) may affect the abundance of exosomal miRNAs in HM, providing a mechanism for growth and adiposity variation in infants of mothers with GDM in early life. Therefore, the purposes of this study were to examine the impact of GDM on select miRNAs (miRNA-148a, miRNA-30b, miRNA-let-7a, and miRNA-let-7d) involved in metabolism and to examine the association of these miRNAs with measures of infant body composition in the first 6 months of life. METHODS: Milk samples were collected from a cohort of 94 mothers (62 mothers without GDM and 32 mothers with GDM) matched on body mass index strata at 1 month post partum. miRNA abundance was measured by real-time polymerase chain reaction. Linear regression models were used to examine potential differences in miRNA abundance in women with and without GDM, testing associations between miRNA abundance and infant growth and body composition measures from 1 to 6 months. FINDINGS: The abundances of miRNA-148a, miRNA-30b, miRNA-let-7a, and miRNA-let-7d were reduced in milk from mothers with GDM. Independent of GDM status, higher maternal diet quality was associated with increased abundance of each of the measured miRNAs. miRNA-148a was negatively associated with infant weight, percentage of body fat, and fat mass, whereas miRNA-30b was positively associated with infant weight and fat mass at 1 month of age. There was no association of milk miRNA-148a and miRNA-30b with infant weight at 1 month of age or with body composition measures at 3 months of age; however, miRNA-148a was negatively associated with infant weight at 6 months of age. IMPLICATIONS: If supported by randomized dietary supplementation or other intervention trials, HM miRNAs may be a therapeutic target to mitigate risk of metabolic outcomes in offspring of women with GDM.
Authors: Susan M Krebs-Smith; TusaRebecca E Pannucci; Amy F Subar; Sharon I Kirkpatrick; Jennifer L Lerman; Janet A Tooze; Magdalena M Wilson; Jill Reedy Journal: J Acad Nutr Diet Date: 2018-09 Impact factor: 4.910
Authors: Alexandre Wagschal; S Hani Najafi-Shoushtari; Lifeng Wang; Leigh Goedeke; Sumita Sinha; Andrew S deLemos; Josh C Black; Cristina M Ramírez; Yingxia Li; Ryan Tewhey; Ida Hatoum; Naisha Shah; Yong Lu; Fjoralba Kristo; Nikolaos Psychogios; Vladimir Vrbanac; Yi-Chien Lu; Timothy Hla; Rafael de Cabo; John S Tsang; Eric Schadt; Pardis C Sabeti; Sekar Kathiresan; David E Cohen; Johnathan Whetstine; Raymond T Chung; Carlos Fernández-Hernando; Lee M Kaplan; Andre Bernards; Robert E Gerszten; Anders M Näär Journal: Nat Med Date: 2015-10-26 Impact factor: 53.440
Authors: R J Moon; N C Harvey; S M Robinson; G Ntani; J H Davies; H M Inskip; K M Godfrey; E M Dennison; P C Calder; C Cooper Journal: J Clin Endocrinol Metab Date: 2012-11-16 Impact factor: 5.958
Authors: Pieter Mestdagh; Pieter Van Vlierberghe; An De Weer; Daniel Muth; Frank Westermann; Frank Speleman; Jo Vandesompele Journal: Genome Biol Date: 2009-06-16 Impact factor: 13.583
Authors: Majed A Suwaydi; Xiaojie Zhou; Sharon L Perrella; Mary E Wlodek; Ching Tat Lai; Zoya Gridneva; Donna T Geddes Journal: Nutrients Date: 2022-09-01 Impact factor: 6.706